Kroiss M, Megerle F, Kurlbaum M, et al. - Experts conducted a retrospective cohort to determine the clinical utility and safety of cabozantinib (CABO) monotherapy in adrenocortical carcinoma (ACC). For this study, they included 16 individuals selecting with three referral centers for ACC in Germany and United States. In 7/16 patients, plasma concentration was < 2 mg/L and discontinued > 12 months in 6 additional patients before CABO use. CABO concentration was in the expected steady state range in 4/5 cases with available plasma samples. They noted adverse events of grade 1/2 and 3 in 13 and 3 patients, respectively, and consistent with the known safety profile of CABO. After failing prior treatments, CABO monotherapy can be considered as a safe and effective monotherapy in advanced ACC. Accordingly, in ACC individuals, prospective examination of CABO is needed.